Review



mouse fabp4 elisa kit  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Elabscience Biotechnology mouse fabp4 elisa kit
    The expression of <t>FABP4</t> in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM
    Mouse Fabp4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse fabp4 elisa kit/product/Elabscience Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse fabp4 elisa kit - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis"

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    Journal: Bone Research

    doi: 10.1038/s41413-022-00211-2

    The expression of FABP4 in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM
    Figure Legend Snippet: The expression of FABP4 in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemical staining, Control, Western Blot, Real-time Polymerase Chain Reaction, Comparison

    The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. a , b Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (PB), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (SB) ( n = 3 per group). Scale bar: 100 µm. c Immunoblot analysis of FABP4 and VEGFα in HUVECs cultured with C, P, PB, S, or SB for 24 h. d , g Representative images and quantification of BrdU (green) immunofluorescence ( d ) and Transwell assays ( g ) in HUVECs and FLSs treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). Scale bar: 25 µm, 100 µm. e , f Immunoblot analysis of ERK1/2, p-ERK1/2, P65, and p-P65 in HUVECs ( e ) and FLSs ( f ) treated with C, P, PB, S, or SB for 1 h. h Toluidine blue staining of ATDC5 cells treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). i Immunoblot analysis of FABP4, MMP13, Sox9, and Col2a1 in primary chondrocytes treated with C, P, PB, S, or SB for 24 h. j Immunoblot analysis of P65 and p-P65 in primary chondrocytes treated with C, P, PB, S, or SB for 1 h. One-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; # P < 0.05, ## P < 0.01 compared to the control. The data are shown as the mean ± SEM
    Figure Legend Snippet: The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. a , b Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (PB), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (SB) ( n = 3 per group). Scale bar: 100 µm. c Immunoblot analysis of FABP4 and VEGFα in HUVECs cultured with C, P, PB, S, or SB for 24 h. d , g Representative images and quantification of BrdU (green) immunofluorescence ( d ) and Transwell assays ( g ) in HUVECs and FLSs treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). Scale bar: 25 µm, 100 µm. e , f Immunoblot analysis of ERK1/2, p-ERK1/2, P65, and p-P65 in HUVECs ( e ) and FLSs ( f ) treated with C, P, PB, S, or SB for 1 h. h Toluidine blue staining of ATDC5 cells treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). i Immunoblot analysis of FABP4, MMP13, Sox9, and Col2a1 in primary chondrocytes treated with C, P, PB, S, or SB for 24 h. j Immunoblot analysis of P65 and p-P65 in primary chondrocytes treated with C, P, PB, S, or SB for 1 h. One-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; # P < 0.05, ## P < 0.01 compared to the control. The data are shown as the mean ± SEM

    Techniques Used: In Vitro, Tube Formation Assay, Cell Culture, Western Blot, Immunofluorescence, Staining, Comparison, Control

    Recombinant FABP4 exacerbates the development of RA in C57BL/6 J mice. a Representative images and quantitative analysis of FABP4 were assessed by immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. b – i Representative images and quantification of Vimentin and MMP3 coimmunostaining ( b , f ), CD31 and EMCN coimmunostaining ( c , g ), Col2a1 immunofluorescence staining ( d , h ), and MMP13 immunohistochemical staining ( e , i ) in the knee joints of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm, 25 µm, and 100 µm. One-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM
    Figure Legend Snippet: Recombinant FABP4 exacerbates the development of RA in C57BL/6 J mice. a Representative images and quantitative analysis of FABP4 were assessed by immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. b – i Representative images and quantification of Vimentin and MMP3 coimmunostaining ( b , f ), CD31 and EMCN coimmunostaining ( c , g ), Col2a1 immunofluorescence staining ( d , h ), and MMP13 immunohistochemical staining ( e , i ) in the knee joints of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm, 25 µm, and 100 µm. One-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM

    Techniques Used: Recombinant, Immunohistochemical staining, Staining, Control, Immunofluorescence, Comparison

    Activation of the mTORC1 pathway enhances the secretion of FABP4 by M1-polarized macrophages to exacerbate RA progression. a , b Representative images and quantification of F4/80 and pS6 coimmunostaining in the mouse ( n = 10 per group) ( a ) and human synovium ( n = 16 per group) ( b ) of the control and RA groups. Scale bar: 12.5 µm. c Western blot showing S6 and pS6 in human synovial tissue. d Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with LPS or rapamycin. e Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs stimulated with LPS or rapamycin ( n = 3 per group). Scale bar: 100 µm. f Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with MHY1485 or rapamycin. g Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs treated with MHY1485 or rapamycin ( n = 3 per group). Scale bar: 100 µm. h Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs from control and TSC1KO mice. i Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of wild-type and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. j Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f–j Representative images ( f ) and quantification of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM
    Figure Legend Snippet: Activation of the mTORC1 pathway enhances the secretion of FABP4 by M1-polarized macrophages to exacerbate RA progression. a , b Representative images and quantification of F4/80 and pS6 coimmunostaining in the mouse ( n = 10 per group) ( a ) and human synovium ( n = 16 per group) ( b ) of the control and RA groups. Scale bar: 12.5 µm. c Western blot showing S6 and pS6 in human synovial tissue. d Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with LPS or rapamycin. e Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs stimulated with LPS or rapamycin ( n = 3 per group). Scale bar: 100 µm. f Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with MHY1485 or rapamycin. g Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs treated with MHY1485 or rapamycin ( n = 3 per group). Scale bar: 100 µm. h Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs from control and TSC1KO mice. i Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of wild-type and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. j Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f–j Representative images ( f ) and quantification of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM

    Techniques Used: Activation Assay, Control, Western Blot, Immunofluorescence, Staining, Immunohistochemical staining, Comparison

    Inhibition of the mTORC1 pathway reduces FABP4 secretion by M1-polarized macrophages to attenuate RA progression. a Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. b – e Representative images ( b ) and quantitative analysis of FABP4 immunohistochemical staining ( c ) and coimmunostaining of FABP4 with F4/80 ( d ) or NOS2 ( e ) in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f – j Representative images ( f ) and quantitative analysis of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test. ** P < 0.01. The data are shown as the mean ± SEM
    Figure Legend Snippet: Inhibition of the mTORC1 pathway reduces FABP4 secretion by M1-polarized macrophages to attenuate RA progression. a Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. b – e Representative images ( b ) and quantitative analysis of FABP4 immunohistochemical staining ( c ) and coimmunostaining of FABP4 with F4/80 ( d ) or NOS2 ( e ) in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f – j Representative images ( f ) and quantitative analysis of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test. ** P < 0.01. The data are shown as the mean ± SEM

    Techniques Used: Inhibition, Immunohistochemical staining, Staining, Immunofluorescence

    BMS309403 and anagliptin reduce FABP4 expression in murine synovial macrophages. a – c Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. d – f Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 and F4/80 or NOS2 in the synovium of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01. The data are shown as the mean ± SEM
    Figure Legend Snippet: BMS309403 and anagliptin reduce FABP4 expression in murine synovial macrophages. a – c Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. d – f Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 and F4/80 or NOS2 in the synovium of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01. The data are shown as the mean ± SEM

    Techniques Used: Expressing, Immunohistochemical staining, Staining, Comparison

    Inhibiting FABP4 prevents RA development. a – d Representative images of Vimentin and MMP3 coimmunostaining ( a ), CD31 and EMCN coimmunostaining ( b ), Col2a1 immunofluorescence staining ( c ), and immunohistochemical staining of MMP13 ( D ) in the knee joints of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling. Scale bar: 12.5 µm, 25 µm, and 100 µm. e – h Representative images of Vimentin and MMP3 coimmunostaining ( e ), CD31 and EMCN coimmunostaining ( f ), Col2a1 immunofluorescence staining ( g ), and immunohistochemical staining of MMP13 ( h ) in the knee joints of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks. Scale bar: 12.5 µm, 25 µm, and 100 µm. i – l Quantification of Vimentin-MMP3 ( i ), CD31-EMCN ( j ), Col2a1 ( k ), and MMP13 ( l ) in TSC1KO mice treated with vehicle, BMS309403, or anagliptin for 4 and 8 weeks after AIA surgery ( n = 10 per group). m – p Quantification of Vimentin-MMP3 ( m ), CD31-EMCN ( n ), Col2a1 ( o ), and MMP13 ( p ) in RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test were used. ** P < 0.01. The data are shown as the mean ± SEM
    Figure Legend Snippet: Inhibiting FABP4 prevents RA development. a – d Representative images of Vimentin and MMP3 coimmunostaining ( a ), CD31 and EMCN coimmunostaining ( b ), Col2a1 immunofluorescence staining ( c ), and immunohistochemical staining of MMP13 ( D ) in the knee joints of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling. Scale bar: 12.5 µm, 25 µm, and 100 µm. e – h Representative images of Vimentin and MMP3 coimmunostaining ( e ), CD31 and EMCN coimmunostaining ( f ), Col2a1 immunofluorescence staining ( g ), and immunohistochemical staining of MMP13 ( h ) in the knee joints of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks. Scale bar: 12.5 µm, 25 µm, and 100 µm. i – l Quantification of Vimentin-MMP3 ( i ), CD31-EMCN ( j ), Col2a1 ( k ), and MMP13 ( l ) in TSC1KO mice treated with vehicle, BMS309403, or anagliptin for 4 and 8 weeks after AIA surgery ( n = 10 per group). m – p Quantification of Vimentin-MMP3 ( m ), CD31-EMCN ( n ), Col2a1 ( o ), and MMP13 ( p ) in RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test were used. ** P < 0.01. The data are shown as the mean ± SEM

    Techniques Used: Immunofluorescence, Staining, Immunohistochemical staining, Comparison



    Similar Products

    fabp4 novus biologicals  (Novus Biologicals)
    93
    Novus Biologicals fabp4 novus biologicals
    Fabp4 Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fabp4 novus biologicals/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    fabp4 novus biologicals - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    protein fabp elisa kit  (Cusabio)
    93
    Cusabio protein fabp elisa kit
    Figure 3. Tryptophan alleviates CRS-induced intestine leakage and epithelial apoptosis. (A) Serum intestinal fatty acid-binding protein content by <t>ELISA;</t> (B) FITC-dextran content in serum; (C) TUNEL staining plots; (D) TUNEL-positive cell counts; different letters denote significant differences between groups, p < 0.05. Ctrl refers to control group.
    Protein Fabp Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protein fabp elisa kit/product/Cusabio
    Average 93 stars, based on 1 article reviews
    protein fabp elisa kit - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    fabp4  (Cusabio)
    93
    Cusabio fabp4
    AOPPs accumulation was accompanied by the bone-fat imbalance during skeletal aging. A Serum AOPPs levels in young mice (3-month-old) and aged mice (18-month-old) (n = 6). B AOPPs relative levels in bone marrow from young and aged mice (n = 6). C Serum ALP level (n = 6). D Serum <t>FABP4</t> level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from young and aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in Bone mineral density (BMD), Trabecular Bone Volume/Total Volume (Tb.BV/TV), Trabecular Number (Tb.N), Trabecular thickness (Tb.Th), Trabecular Separation (Tb.Sp), Cortical Thickness (Ct.Th) and Cortical Bone Area (Ct.BArea) (n = 6). W-Y The correlation analysis of serum AOPPs and BMD, ALP, FABP4. Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. young mice group (Student's t test).
    Fabp4, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fabp4/product/Cusabio
    Average 93 stars, based on 1 article reviews
    fabp4 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    csb el007945mo  (Cusabio)
    93
    Cusabio csb el007945mo
    AOPPs accumulation was accompanied by the bone-fat imbalance during skeletal aging. A Serum AOPPs levels in young mice (3-month-old) and aged mice (18-month-old) (n = 6). B AOPPs relative levels in bone marrow from young and aged mice (n = 6). C Serum ALP level (n = 6). D Serum <t>FABP4</t> level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from young and aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in Bone mineral density (BMD), Trabecular Bone Volume/Total Volume (Tb.BV/TV), Trabecular Number (Tb.N), Trabecular thickness (Tb.Th), Trabecular Separation (Tb.Sp), Cortical Thickness (Ct.Th) and Cortical Bone Area (Ct.BArea) (n = 6). W-Y The correlation analysis of serum AOPPs and BMD, ALP, FABP4. Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. young mice group (Student's t test).
    Csb El007945mo, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csb el007945mo/product/Cusabio
    Average 93 stars, based on 1 article reviews
    csb el007945mo - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    circulex mouse fabp4/a-fabp elisa kit  (MBL International)
    90
    MBL International circulex mouse fabp4/a-fabp elisa kit
    AOPPs accumulation was accompanied by the bone-fat imbalance during skeletal aging. A Serum AOPPs levels in young mice (3-month-old) and aged mice (18-month-old) (n = 6). B AOPPs relative levels in bone marrow from young and aged mice (n = 6). C Serum ALP level (n = 6). D Serum <t>FABP4</t> level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from young and aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in Bone mineral density (BMD), Trabecular Bone Volume/Total Volume (Tb.BV/TV), Trabecular Number (Tb.N), Trabecular thickness (Tb.Th), Trabecular Separation (Tb.Sp), Cortical Thickness (Ct.Th) and Cortical Bone Area (Ct.BArea) (n = 6). W-Y The correlation analysis of serum AOPPs and BMD, ALP, FABP4. Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. young mice group (Student's t test).
    Circulex Mouse Fabp4/A Fabp Elisa Kit, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/circulex mouse fabp4/a-fabp elisa kit/product/MBL International
    Average 90 stars, based on 1 article reviews
    circulex mouse fabp4/a-fabp elisa kit - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse fabp4 elisa kit  (Elabscience Biotechnology)
    90
    Elabscience Biotechnology mouse fabp4 elisa kit
    The expression of <t>FABP4</t> in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM
    Mouse Fabp4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse fabp4 elisa kit/product/Elabscience Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse fabp4 elisa kit - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse and rat fabp4 elisa kits  (Boster Bio)
    90
    Boster Bio mouse and rat fabp4 elisa kits
    The expression of <t>FABP4</t> in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM
    Mouse And Rat Fabp4 Elisa Kits, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse and rat fabp4 elisa kits/product/Boster Bio
    Average 90 stars, based on 1 article reviews
    mouse and rat fabp4 elisa kits - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse fabp4 enzyme linked immunosorbent assay (elisa) kit  (Boster Bio)
    93
    Boster Bio mouse fabp4 enzyme linked immunosorbent assay (elisa) kit
    The expression of <t>FABP4</t> in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM
    Mouse Fabp4 Enzyme Linked Immunosorbent Assay (Elisa) Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse fabp4 enzyme linked immunosorbent assay (elisa) kit/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    mouse fabp4 enzyme linked immunosorbent assay (elisa) kit - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 3. Tryptophan alleviates CRS-induced intestine leakage and epithelial apoptosis. (A) Serum intestinal fatty acid-binding protein content by ELISA; (B) FITC-dextran content in serum; (C) TUNEL staining plots; (D) TUNEL-positive cell counts; different letters denote significant differences between groups, p < 0.05. Ctrl refers to control group.

    Journal: Nutrients

    Article Title: Tryptophan Attenuates Chronic Restraint Stress-Induced Intestinal Injury Through Modulation of Intestinal Barrier Integrity and Gut Microbiota Homeostasis

    doi: 10.3390/nu17060975

    Figure Lengend Snippet: Figure 3. Tryptophan alleviates CRS-induced intestine leakage and epithelial apoptosis. (A) Serum intestinal fatty acid-binding protein content by ELISA; (B) FITC-dextran content in serum; (C) TUNEL staining plots; (D) TUNEL-positive cell counts; different letters denote significant differences between groups, p < 0.05. Ctrl refers to control group.

    Article Snippet: We obtained the Mouse Corticosterone (CORT) ELISA Kit (Elabscience, Shanghai, China), FITC—dextran (4 kD) (Sigma, Saint Louis, MI, USA); the mouse intestinal fatty acid-binding protein (FABP) ELISA Kit (CUSABIO, Wuhan, China); and all of the 11 SCFA standards (ZZ Standards Co., Ltd., Shanghai, China).

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, TUNEL Assay, Staining, Control

    AOPPs accumulation was accompanied by the bone-fat imbalance during skeletal aging. A Serum AOPPs levels in young mice (3-month-old) and aged mice (18-month-old) (n = 6). B AOPPs relative levels in bone marrow from young and aged mice (n = 6). C Serum ALP level (n = 6). D Serum FABP4 level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from young and aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in Bone mineral density (BMD), Trabecular Bone Volume/Total Volume (Tb.BV/TV), Trabecular Number (Tb.N), Trabecular thickness (Tb.Th), Trabecular Separation (Tb.Sp), Cortical Thickness (Ct.Th) and Cortical Bone Area (Ct.BArea) (n = 6). W-Y The correlation analysis of serum AOPPs and BMD, ALP, FABP4. Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. young mice group (Student's t test).

    Journal: Journal of Orthopaedic Translation

    Article Title: Accumulation of advanced oxidation protein products aggravates bone-fat imbalance during skeletal aging

    doi: 10.1016/j.jot.2024.12.010

    Figure Lengend Snippet: AOPPs accumulation was accompanied by the bone-fat imbalance during skeletal aging. A Serum AOPPs levels in young mice (3-month-old) and aged mice (18-month-old) (n = 6). B AOPPs relative levels in bone marrow from young and aged mice (n = 6). C Serum ALP level (n = 6). D Serum FABP4 level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from young and aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in Bone mineral density (BMD), Trabecular Bone Volume/Total Volume (Tb.BV/TV), Trabecular Number (Tb.N), Trabecular thickness (Tb.Th), Trabecular Separation (Tb.Sp), Cortical Thickness (Ct.Th) and Cortical Bone Area (Ct.BArea) (n = 6). W-Y The correlation analysis of serum AOPPs and BMD, ALP, FABP4. Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. young mice group (Student's t test).

    Article Snippet: The kit for mouse ALP was from CUSIBIO (CSB-E11914m; CUSABIO), and the level of FABP4 was examined using another kit (CSB-EL007945MO; CUSABIO).

    Techniques: Staining, Immunohistochemistry, Micro-CT, Expressing

    Decreased AOPPs level by antioxidant leaded to higher bone formation and lower marrow adiposity in aged mice. A Serum AOPPs levels in aged and NAC-treated aged mice (n = 6). B AOPPs relative levels in bone marrow from aged and NAC-treated aged mice (n = 6). C Serum ALP level (n = 6). D Serum FABP4 level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from aged and NAC-treated aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in BMD, Tb.BV/TV, Tb.N, Tb.Th, Tb.Sp, Ct.Th and Ct.BArea (n = 6). Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. aged mice group (Student's t test).

    Journal: Journal of Orthopaedic Translation

    Article Title: Accumulation of advanced oxidation protein products aggravates bone-fat imbalance during skeletal aging

    doi: 10.1016/j.jot.2024.12.010

    Figure Lengend Snippet: Decreased AOPPs level by antioxidant leaded to higher bone formation and lower marrow adiposity in aged mice. A Serum AOPPs levels in aged and NAC-treated aged mice (n = 6). B AOPPs relative levels in bone marrow from aged and NAC-treated aged mice (n = 6). C Serum ALP level (n = 6). D Serum FABP4 level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculas. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from aged and NAC-treated aged mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in BMD, Tb.BV/TV, Tb.N, Tb.Th, Tb.Sp, Ct.Th and Ct.BArea (n = 6). Data were shown as mean ± SD. ∗P < 0.05, ∗∗P < 0.01 vs. aged mice group (Student's t test).

    Article Snippet: The kit for mouse ALP was from CUSIBIO (CSB-E11914m; CUSABIO), and the level of FABP4 was examined using another kit (CSB-EL007945MO; CUSABIO).

    Techniques: Staining, Immunohistochemistry, Micro-CT, Expressing

    Chronic AOPPs loading lead to the bone-fat imbalance in young mice. A Serum AOPPs levels in 6-month-old mice and AOPPs-intervened mice (n = 6). B AOPPs relative levels in bone marrow from 6-month-old mice and AOPPs-intervened mice (n = 6). C Serum ALP level (n = 6). D Serum FABP4 level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculae. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from AOPPs-intervened mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in BMD, Tb.BV/TV, Tb.N, Tb.Th, Tb.Sp, Ct.Th and Ct.BArea (n = 6). Data were presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01 vs. PBS group (one-way ANOVA).

    Journal: Journal of Orthopaedic Translation

    Article Title: Accumulation of advanced oxidation protein products aggravates bone-fat imbalance during skeletal aging

    doi: 10.1016/j.jot.2024.12.010

    Figure Lengend Snippet: Chronic AOPPs loading lead to the bone-fat imbalance in young mice. A Serum AOPPs levels in 6-month-old mice and AOPPs-intervened mice (n = 6). B AOPPs relative levels in bone marrow from 6-month-old mice and AOPPs-intervened mice (n = 6). C Serum ALP level (n = 6). D Serum FABP4 level (n = 6). E, F HE staining of bone trabeculae and adipocytes in distal femora, and the area of fat vacuoles was quantified. Scale bars = 100 μm. G, H IHC staining for OCN and number of osteoblasts in distal femoral trabeculae. Scale bars = 20 μm. I, J IHC staining for FABP4 and number of adipocytes. Scale bars = 20 μm. K, L Micro-CT scanning of osmium tetroxide-stained tibia and MAT content below the growth plate (n = 3). M, N The protein and mRNA expression of OCN and PPARγ in proximal tibial metaphysis. O Representative micro-CT images of distal femora from AOPPs-intervened mice (n = 6) (Scale bars = 1 mm). P-V Quantitative trabecular and cortical bone parameters data were displayed in BMD, Tb.BV/TV, Tb.N, Tb.Th, Tb.Sp, Ct.Th and Ct.BArea (n = 6). Data were presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01 vs. PBS group (one-way ANOVA).

    Article Snippet: The kit for mouse ALP was from CUSIBIO (CSB-E11914m; CUSABIO), and the level of FABP4 was examined using another kit (CSB-EL007945MO; CUSABIO).

    Techniques: Staining, Immunohistochemistry, Micro-CT, Expressing

    The expression of FABP4 in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: The expression of FABP4 in the RA mouse model, BMDMs and RA patients. a , b FABP4 concentrations in the synovial fluid ( a ) and serum ( b ) of controls and RA patients ( n = 8 per group) were assessed by ELISA. C Representative images and quantification of HE staining and FABP4 immunohistochemical staining in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm, 100 μm and 200 μm. d Representative images and quantitative analysis of coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 μm. e Representative images and quantification of safranin O and fast green staining and FABP4 immunohistochemical staining in knee cartilage from controls and C57BL/6 J mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 50 μm and 100 μm. f Western blot showing FABP4 and NOS2 in BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h. g Quantitative PCR analysis of NOS2, Arg-1, and FABP4 mRNA expression in BMDMs ( n = 3 per group). h FABP4 concentrations in the supernatant of BMDMs stimulated with 50, 200, or 500 ng·mL −1 LPS for 12 h or 24 h ( n = 3 per group) were assessed by ELISA. Student’s t -test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; ns, no significance. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemical staining, Control, Western Blot, Real-time Polymerase Chain Reaction, Comparison

    The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. a , b Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (PB), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (SB) ( n = 3 per group). Scale bar: 100 µm. c Immunoblot analysis of FABP4 and VEGFα in HUVECs cultured with C, P, PB, S, or SB for 24 h. d , g Representative images and quantification of BrdU (green) immunofluorescence ( d ) and Transwell assays ( g ) in HUVECs and FLSs treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). Scale bar: 25 µm, 100 µm. e , f Immunoblot analysis of ERK1/2, p-ERK1/2, P65, and p-P65 in HUVECs ( e ) and FLSs ( f ) treated with C, P, PB, S, or SB for 1 h. h Toluidine blue staining of ATDC5 cells treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). i Immunoblot analysis of FABP4, MMP13, Sox9, and Col2a1 in primary chondrocytes treated with C, P, PB, S, or SB for 24 h. j Immunoblot analysis of P65 and p-P65 in primary chondrocytes treated with C, P, PB, S, or SB for 1 h. One-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; # P < 0.05, ## P < 0.01 compared to the control. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. a , b Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (PB), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (SB) ( n = 3 per group). Scale bar: 100 µm. c Immunoblot analysis of FABP4 and VEGFα in HUVECs cultured with C, P, PB, S, or SB for 24 h. d , g Representative images and quantification of BrdU (green) immunofluorescence ( d ) and Transwell assays ( g ) in HUVECs and FLSs treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). Scale bar: 25 µm, 100 µm. e , f Immunoblot analysis of ERK1/2, p-ERK1/2, P65, and p-P65 in HUVECs ( e ) and FLSs ( f ) treated with C, P, PB, S, or SB for 1 h. h Toluidine blue staining of ATDC5 cells treated with C, P, PB, S, or SB for 24 h ( n = 3 per group). i Immunoblot analysis of FABP4, MMP13, Sox9, and Col2a1 in primary chondrocytes treated with C, P, PB, S, or SB for 24 h. j Immunoblot analysis of P65 and p-P65 in primary chondrocytes treated with C, P, PB, S, or SB for 1 h. One-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01; # P < 0.05, ## P < 0.01 compared to the control. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: In Vitro, Tube Formation Assay, Cell Culture, Western Blot, Immunofluorescence, Staining, Comparison, Control

    Recombinant FABP4 exacerbates the development of RA in C57BL/6 J mice. a Representative images and quantitative analysis of FABP4 were assessed by immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. b – i Representative images and quantification of Vimentin and MMP3 coimmunostaining ( b , f ), CD31 and EMCN coimmunostaining ( c , g ), Col2a1 immunofluorescence staining ( d , h ), and MMP13 immunohistochemical staining ( e , i ) in the knee joints of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm, 25 µm, and 100 µm. One-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: Recombinant FABP4 exacerbates the development of RA in C57BL/6 J mice. a Representative images and quantitative analysis of FABP4 were assessed by immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. b – i Representative images and quantification of Vimentin and MMP3 coimmunostaining ( b , f ), CD31 and EMCN coimmunostaining ( c , g ), Col2a1 immunofluorescence staining ( d , h ), and MMP13 immunohistochemical staining ( e , i ) in the knee joints of control and RA mice treated with vehicle or rmFABP4 for 4 and 8 weeks ( n = 10 per group). Scale bars: 12.5 µm, 25 µm, and 100 µm. One-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: Recombinant, Immunohistochemical staining, Staining, Control, Immunofluorescence, Comparison

    Activation of the mTORC1 pathway enhances the secretion of FABP4 by M1-polarized macrophages to exacerbate RA progression. a , b Representative images and quantification of F4/80 and pS6 coimmunostaining in the mouse ( n = 10 per group) ( a ) and human synovium ( n = 16 per group) ( b ) of the control and RA groups. Scale bar: 12.5 µm. c Western blot showing S6 and pS6 in human synovial tissue. d Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with LPS or rapamycin. e Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs stimulated with LPS or rapamycin ( n = 3 per group). Scale bar: 100 µm. f Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with MHY1485 or rapamycin. g Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs treated with MHY1485 or rapamycin ( n = 3 per group). Scale bar: 100 µm. h Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs from control and TSC1KO mice. i Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of wild-type and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. j Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f–j Representative images ( f ) and quantification of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: Activation of the mTORC1 pathway enhances the secretion of FABP4 by M1-polarized macrophages to exacerbate RA progression. a , b Representative images and quantification of F4/80 and pS6 coimmunostaining in the mouse ( n = 10 per group) ( a ) and human synovium ( n = 16 per group) ( b ) of the control and RA groups. Scale bar: 12.5 µm. c Western blot showing S6 and pS6 in human synovial tissue. d Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with LPS or rapamycin. e Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs stimulated with LPS or rapamycin ( n = 3 per group). Scale bar: 100 µm. f Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs treated with MHY1485 or rapamycin. g Representative immunofluorescence staining images and quantitative analysis of FABP4 in BMDMs treated with MHY1485 or rapamycin ( n = 3 per group). Scale bar: 100 µm. h Western blot showing FABP4, NOS2, S6 and pS6 in BMDMs from control and TSC1KO mice. i Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of wild-type and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. j Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of control and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f–j Representative images ( f ) and quantification of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and TSC1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. ** P < 0.01. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: Activation Assay, Control, Western Blot, Immunofluorescence, Staining, Immunohistochemical staining, Comparison

    Inhibition of the mTORC1 pathway reduces FABP4 secretion by M1-polarized macrophages to attenuate RA progression. a Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. b – e Representative images ( b ) and quantitative analysis of FABP4 immunohistochemical staining ( c ) and coimmunostaining of FABP4 with F4/80 ( d ) or NOS2 ( e ) in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f – j Representative images ( f ) and quantitative analysis of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test. ** P < 0.01. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: Inhibition of the mTORC1 pathway reduces FABP4 secretion by M1-polarized macrophages to attenuate RA progression. a Representative images and quantification of F4/80 and pS6 coimmunostaining in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm. b – e Representative images ( b ) and quantitative analysis of FABP4 immunohistochemical staining ( c ) and coimmunostaining of FABP4 with F4/80 ( d ) or NOS2 ( e ) in the synovium of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bars: 12.5 µm and 100 µm. f – j Representative images ( f ) and quantitative analysis of Vimentin and MMP3 coimmunostaining ( g ), CD31 and EMCN coimmunostaining ( h ), Col2a1 immunofluorescence staining ( i ), and MMP13 immunohistochemical staining ( j ) in the knee joints of controls and Rheb1KO mice at 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm, 25 µm, and 100 µm. Student’s t -test. ** P < 0.01. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: Inhibition, Immunohistochemical staining, Staining, Immunofluorescence

    BMS309403 and anagliptin reduce FABP4 expression in murine synovial macrophages. a – c Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. d – f Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 and F4/80 or NOS2 in the synovium of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: BMS309403 and anagliptin reduce FABP4 expression in murine synovial macrophages. a – c Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. d – f Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 and F4/80 or NOS2 in the synovium of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Scale bar: 12.5 µm and 100 µm. Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test. * P < 0.05, ** P < 0.01. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: Expressing, Immunohistochemical staining, Staining, Comparison

    Inhibiting FABP4 prevents RA development. a – d Representative images of Vimentin and MMP3 coimmunostaining ( a ), CD31 and EMCN coimmunostaining ( b ), Col2a1 immunofluorescence staining ( c ), and immunohistochemical staining of MMP13 ( D ) in the knee joints of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling. Scale bar: 12.5 µm, 25 µm, and 100 µm. e – h Representative images of Vimentin and MMP3 coimmunostaining ( e ), CD31 and EMCN coimmunostaining ( f ), Col2a1 immunofluorescence staining ( g ), and immunohistochemical staining of MMP13 ( h ) in the knee joints of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks. Scale bar: 12.5 µm, 25 µm, and 100 µm. i – l Quantification of Vimentin-MMP3 ( i ), CD31-EMCN ( j ), Col2a1 ( k ), and MMP13 ( l ) in TSC1KO mice treated with vehicle, BMS309403, or anagliptin for 4 and 8 weeks after AIA surgery ( n = 10 per group). m – p Quantification of Vimentin-MMP3 ( m ), CD31-EMCN ( n ), Col2a1 ( o ), and MMP13 ( p ) in RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test were used. ** P < 0.01. The data are shown as the mean ± SEM

    Journal: Bone Research

    Article Title: FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis

    doi: 10.1038/s41413-022-00211-2

    Figure Lengend Snippet: Inhibiting FABP4 prevents RA development. a – d Representative images of Vimentin and MMP3 coimmunostaining ( a ), CD31 and EMCN coimmunostaining ( b ), Col2a1 immunofluorescence staining ( c ), and immunohistochemical staining of MMP13 ( D ) in the knee joints of TSC1KO mice treated with vehicle, BMS309403 or anagliptin for 4 and 8 weeks after AIA modeling. Scale bar: 12.5 µm, 25 µm, and 100 µm. e – h Representative images of Vimentin and MMP3 coimmunostaining ( e ), CD31 and EMCN coimmunostaining ( f ), Col2a1 immunofluorescence staining ( g ), and immunohistochemical staining of MMP13 ( h ) in the knee joints of RA mice treated with vehicle or BMS309403 for 4 and 8 weeks. Scale bar: 12.5 µm, 25 µm, and 100 µm. i – l Quantification of Vimentin-MMP3 ( i ), CD31-EMCN ( j ), Col2a1 ( k ), and MMP13 ( l ) in TSC1KO mice treated with vehicle, BMS309403, or anagliptin for 4 and 8 weeks after AIA surgery ( n = 10 per group). m – p Quantification of Vimentin-MMP3 ( m ), CD31-EMCN ( n ), Col2a1 ( o ), and MMP13 ( p ) in RA mice treated with vehicle or BMS309403 for 4 and 8 weeks ( n = 10 per group). Student’s t -test or one-way ANOVA and Tukey’s multiple comparison test were used. ** P < 0.01. The data are shown as the mean ± SEM

    Article Snippet: We used human and mouse FABP4 ELISA kits (Elabscience Biotechnology, Bethesda, MD, USA: #E-EL-H0285c and #E-EL-M2404c) to analyze the level of FABP4 in the supernatant of macrophages stimulated with lipopolysaccharide (LPS), the serum of C57BL/6 J and TSC1KO mice, and human serum and synovial fluid.

    Techniques: Immunofluorescence, Staining, Immunohistochemical staining, Comparison